22 May 2013
Keywords: shire, adhd, drug, impresses, phase, iii, trial
Article | 27 November 2006
UK-based drugmaker Shire says that data from a Phase III trial of its drug SPD503 (guanfacine extended release), administered as ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
27 November 2006
21 May 2013
© 2013 thepharmaletter.com